Breaking News Instant updates and real-time market news.

DRRX

Durect

$1.31

0.01 (0.77%)

, NVS

Novartis

$80.83

0.38 (0.47%)

07:03
06/19/17
06/19
07:03
06/19/17
07:03

Durect collaboration with Sandoz clears HSR review, now effective

DURECT (DRRX) announced that the previously disclosed development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States DURECT's POSIMIR, an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery, has cleared review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and has become effective. Under the terms of the agreement, Sandoz has made an upfront payment to DURECT of $20M, with the potential for up to an additional $43M in development and regulatory milestones, up to an additional $230M in sales-based milestones, as well as a tiered double-digit royalty on product sales in the United States. DURECT remains responsible for the completion of the ongoing PERSIST Phase 3 clinical trial for POSIMIR as well as FDA interactions through approval.

DRRX

Durect

$1.31

0.01 (0.77%)

NVS

Novartis

$80.83

0.38 (0.47%)

  • 26

    Jun

DRRX Durect
$1.31

0.01 (0.77%)

02/28/17
HCWC
02/28/17
INITIATION
Target $3
HCWC
Buy
Durect assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce assumed coverage of Durect with a Buy rating and $3 price target.
NVS Novartis
$80.83

0.38 (0.47%)

06/08/17
06/08/17
UPGRADE
Target $100

Buy
Kite Pharma upgraded to Buy on Axi-Cel manufacturing edge at BTIG
As previously reported, BTIG analyst Dane Leone upgraded Kite Pharma (KITE) to Buy from Neutral and set a $100 price target on the shares. Data from Novartis (NVS) and Juno (JUNO) have failed to deliver any recognizable differentiation, though Leone gives Kite "a clear win" for the manufacturing of Axi-Cel versus peers, he tells investors. The analyst sees Kite having the cleanest pathway to approval for diffuse large B-cell lymphoma and, given Kite's manufacturing edge, he estimates that Axi-Cel can take about 60% of share within the U.S. DLBCL market.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/06/17
LEER
06/06/17
NO CHANGE
Target $100
LEER
Outperform
bluebird data among most impressive in CAR-T space, says Leerink
Leerink analyst Michael Schmidt says bluebird bio's (BLUE) bb2121 dose-escalation data in multiple myeloma is among the most impressive early data sets he's seen in the CAR-T space to date. The data sets a high bar for the competition, which includes Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS), Schmidt tells investors in a research note. Being one year ahead of the competition provides bluebird and Celgene (CELG) with an ideal position in multiple myeloma, the analyst adds. He keeps an Outperform rating on bluebird shares with a $100 price target.
06/01/17
NEED
06/01/17
NO CHANGE
Target $4.5
NEED
Buy
Cryoport price target raised to $4.50 from $3.50 at Needham
Needham analyst Sean Hannan noted that Novartis (NVS) and Kite Pharma (KITE) both have Biologics License Applications nearing approval for studies believed to be supported by Cryoport (CYRX). Citing his growing comfort on clients' progress toward commercialization, he raised his price target on Cryoport to $4.50 from $3.50 and keeps a Buy rating on the "arms provider" to companies working on emerging regenerative therapies.

TODAY'S FREE FLY STORIES

GTIM

Good Times Restaurants

08:07
06/22/17
06/22
08:07
06/22/17
08:07
Initiation
Good Times Restaurants initiated  »

Good Times Restaurants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$48.43

0.4 (0.83%)

08:07
06/22/17
06/22
08:07
06/22/17
08:07
Hot Stocks
Breaking Hot Stocks news story on American Airlines »

American Airlines: Qatar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

KMX

CarMax

$59.74

0.48 (0.81%)

08:06
06/22/17
06/22
08:06
06/22/17
08:06
Downgrade
CarMax rating change  »

CarMax downgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 30

    Jun

AAL

American Airlines

$48.43

0.4 (0.83%)

08:06
06/22/17
06/22
08:06
06/22/17
08:06
Hot Stocks
American Airlines: Qatar Airways intends to make 'significant' investment »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

ANF

Abercrombie & Fitch

$12.05

-0.16 (-1.31%)

08:06
06/22/17
06/22
08:06
06/22/17
08:06
Upgrade
Abercrombie & Fitch rating change  »

Correction: Abercrombie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:05
06/22/17
06/22
08:05
06/22/17
08:05
General news
Treasury Market Outlook: bonds are little changed »

Treasury Market Outlook:…

WFM

Whole Foods

$43.26

0.48 (1.12%)

, KR

Kroger

$22.37

-0.01 (-0.04%)

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Recommendations
Whole Foods, Kroger, Costco, Target, Wal-Mart, Amazon.com analyst commentary  »

JPMorgan has 'hard…

WFM

Whole Foods

$43.26

0.48 (1.12%)

KR

Kroger

$22.37

-0.01 (-0.04%)

COST

Costco

$163.15

0.25 (0.15%)

TGT

Target

$50.52

-0.39 (-0.77%)

WMT

Wal-Mart

$76.24

0.7 (0.93%)

AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 28

    Jun

  • 23

    Aug

ISBC

Investors Bancorp

$13.08

-0.18 (-1.36%)

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Hot Stocks
Investors Bancorp appoints Michael Fegan Chief Information and Operations Office »

Investors Bank has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JW.A

John Wiley

$51.75

0.4 (0.78%)

, JW.B

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Hot Stocks
John Wiley & Sons raises quarterly dividend 3% to 32c per share »

John Wiley & Sons…

JW.A

John Wiley

$51.75

0.4 (0.78%)

JW.B

JWB

John Wiley & Sons; also tag JWA

JWA

John Wiley & Sons; also tag JWB

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AME

Ametek

$60.51

-1.36 (-2.20%)

, MOCO

Mocon

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Hot Stocks
Ametek completes acquisition of Mocon »

Ametek (AME) announced…

AME

Ametek

$60.51

-1.36 (-2.20%)

MOCO

Mocon

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSE

Trinseo

$65.05

-0.5 (-0.76%)

08:03
06/22/17
06/22
08:03
06/22/17
08:03
Hot Stocks
Trinseo increases quarterly dividend, announces new share repurchase program »

Trinseo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$0.95

0.0471 (5.24%)

08:02
06/22/17
06/22
08:02
06/22/17
08:02
Hot Stocks
Trovagene to provide Trovera tests and services for global pharma company »

Trovagene has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$33.16

0.13 (0.39%)

08:02
06/22/17
06/22
08:02
06/22/17
08:02
Technical Analysis
Technical View: Hain Celestial up after earnings, buybacks, new CFO »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 27

    Jun

TSLA

Tesla

$376.40

4.16 (1.12%)

08:01
06/22/17
06/22
08:01
06/22/17
08:01
Periodicals
Tianjin not participating in Tesla's China project at this time, Reuters says »

Tianjin Motors says it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MNK

Mallinckrodt

$45.37

2.06 (4.76%)

08:00
06/22/17
06/22
08:00
06/22/17
08:00
Options
Mallinckrodt call buyer realizes 74% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:00
06/22/17
06/22
08:00
06/22/17
08:00
General news
Breaking General news story  »

New York Federal Reserve…

ORCL

Oracle

$46.33

0.49 (1.07%)

07:59
06/22/17
06/22
07:59
06/22/17
07:59
Upgrade
Oracle rating change  »

Oracle upgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BRK.A

Berkshire Hathaway

$254,400.00

-1460 (-0.57%)

, BRK.B

Berkshire Hathaway

$169.62

-0.93 (-0.55%)

07:57
06/22/17
06/22
07:57
06/22/17
07:57
Hot Stocks
Berkshire to invest up to C$400M in Home Capital, provide C$2B line of credit »

Canada's Home…

BRK.A

Berkshire Hathaway

$254,400.00

-1460 (-0.57%)

BRK.B

Berkshire Hathaway

$169.62

-0.93 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$153.73

-0.34 (-0.22%)

, AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

07:56
06/22/17
06/22
07:56
06/22/17
07:56
Periodicals
McDonald's teams up with UberEats in Britain, Engadget reports »

McDonald's (MCD) is…

MCD

McDonald's

$153.73

-0.34 (-0.22%)

AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

KMDA

Kamada

$7.50

-0.05 (-0.66%)

07:55
06/22/17
06/22
07:55
06/22/17
07:55
Technical Analysis
Technical View: Kamada dives after withdrawing MAA for AAT therapy with EMA »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

NEP

NextEra Energy Partners

$35.11

0.03 (0.09%)

, NEE

NextEra Energy

$141.06

-0.9 (-0.63%)

07:55
06/22/17
06/22
07:55
06/22/17
07:55
Conference/Events
NextEra Energy and NextEra Energy Partners to hold an investor meeting »

Investor Meeting to be…

NEP

NextEra Energy Partners

$35.11

0.03 (0.09%)

NEE

NextEra Energy

$141.06

-0.9 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

LLY

Eli Lilly

$82.64

-0.11 (-0.13%)

07:55
06/22/17
06/22
07:55
06/22/17
07:55
Conference/Events
FDA Pediatric Oncology Subcommittee of Oncologic Drugs Committee holds a meeting »

The Pediatric Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SPLS

Staples

$8.66

-0.09 (-1.03%)

07:52
06/22/17
06/22
07:52
06/22/17
07:52
Recommendations
Staples analyst commentary  »

Staples LBO could work in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$36.71

0.58 (1.61%)

, QCOM

Qualcomm

$56.33

-0.46 (-0.81%)

07:51
06/22/17
06/22
07:51
06/22/17
07:51
Periodicals
TSMC receives 7nm chip orders from Qualcomm, DigiTimes reports »

TSMC (TSM) has secured…

TSM

TSMC

$36.71

0.58 (1.61%)

QCOM

Qualcomm

$56.33

-0.46 (-0.81%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIC

Otonomy

$17.50

1.45 (9.03%)

07:50
06/22/17
06/22
07:50
06/22/17
07:50
Hot Stocks
Otonomy announces successful end-of-Phase 2 review by FDA for Otiprio »

Otonomy announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.